Amgen Work in process decreased by 2.8% to $3.56B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 18.1%, from $4.34B to $3.56B. Over 4 years (FY 2020 to FY 2024), Work in process shows an upward trend with a 14.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase may indicate production bottlenecks or scaling efforts, while a decrease suggests efficient throughput or reduced manufacturing activity.
Represents the value of goods that have entered the production process but are not yet finished. For a manufacturer like...
Peers in medical device manufacturing typically maintain lean WIP levels to optimize cash conversion cycles.
inv_work_in_progress| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.44B | $2.31B | $2.37B | $2.58B | $2.76B | $2.93B | $3.10B | $2.98B | $3.05B | $2.99B | $5.75B | $5.27B | $4.48B | $4.34B | $4.12B | $3.96B | $3.66B | $3.56B |
| QoQ Change | — | -5.3% | +2.3% | +9.1% | +7.0% | +6.0% | +5.8% | -3.9% | +2.4% | -1.8% | +92.1% | -8.3% | -15.1% | -3.1% | -5.0% | -3.9% | -7.6% | -2.8% |
| YoY Change | — | — | — | — | +13.1% | +26.6% | +30.9% | +15.3% | +10.3% | +2.2% | +85.5% | +77.0% | +46.9% | +45.0% | -28.3% | -24.8% | -18.3% | -18.1% |
| % of Inventories | 59.4% | 55.7% | 57.9% | 58.5% | 60.7% | 61.6% | 62.8% | 59.4% | 61.2% | 59.5% | 60.4% | 60.4% | 56.0% | 58.9% | 58.9% | 58.9% | 55.6% | 56.0% |
| Share Change | — | -3.7pp | +2.2pp | +0.6pp | +2.1pp | +0.9pp | +1.3pp | -3.4pp | +1.8pp | -1.7pp | +0.8pp | +0.0pp | -4.4pp | +3.0pp | -0.1pp | -0.0pp | -3.3pp | +0.5pp |
We use cookies for analytics. See our Privacy and Cookie Policy.